EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis

Andrea Di Giorgio iD, Giambattista Siepe, Francesca Serani, Martina Di Franco iD, Claudio Malizia, Paolo Castellucci, Stefano Fanti, Andrea Farolfi

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07255-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Andrea Di Giorgio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, Bologna, 40138, Italy. andrea.digiorgio2@studio.unibo.it. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Prostatectomy, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the role of PSMA PET/CT-guided salvage radiotherapy (sRT) in improving long-term biochemical recurrence-free survival (bRFS) in patients with biochemical recurrence (BCR) or PSA persistence (PERS) after radical prostatectomy (RP) for localized prostate cancer.

Methods

This single-center retrospective study included 100 patients with BCR or PERS after RP who underwent [⁶⁸Ga]Ga-PSMA-11 PET/CT and sRT according to EAU guidelines. The primary endpoint was bRFS (PSA ≤ 0.2 ng/ml).

Results

Sixty-three patients had BCR and 37 had PERS. Fifteen patients had PSA pre-RT < 0.5 ng/ml, while 75 had PSA pre-RT ≥ 0.5 ng/ml. [⁶⁸Ga]Ga-PSMA-11 PET/CT was positive in 52 patients, with BCR patients more frequently exhibiting local recurrence while PERS patients showed more nodal involvement. Patients with PERS received sRT and androgen deprivation therapy (ADT) in 57% of cases. The hazard ratio (HR) of treatment failure for patients with PSA pre-RT ≥ 0.5 ng/ml vs. < 0.5 ng/ml was 2.2 ( p < 0.039). With a median follow-up of 59 months, treatment failure occurred in 36% of patients, with no difference between BCR and PERS groups. Among those with treatment failure, 64% were [⁶⁸Ga]Ga-PSMA-11 PET/CT positive at recurrence, and 39% received a new PSMA PET/CT-based RT. All patients were alive at the last analysis. Conclusion [⁶⁸Ga]Ga-PSMA-11 PET/CT-guided sRT demonstrates significant long-term efficacy in patients with BCR or PERS after RP, leading to durable PSA response and guiding further treatment decisions.

Trial registration

244/2016/O/Oss8 November 2016 retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsProstatectomyRadiotherapy, Image-GuidedHumansMaleAgedMiddle AgedFollow-Up StudiesRetrospective StudiesGallium RadioisotopesTreatment OutcomeTreatment FailureOligopeptidesProstate-Specific AntigenEdetic AcidSalvage TherapyGallium Isotopes

Stichwörter der Autor:innen

Biochemical recurrencePSMA PET/CTProstate CancerSalvage radiotherapy

Substanzen

gallium 68 PSMA-11Gallium RadioisotopesOligopeptidesProstate-Specific AntigenEdetic AcidGallium Isotopes

Autor:innen und Institutionen

  • Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, Bologna, 40138, Italy. andrea.digiorgio2@studio.unibo.it.
  • Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40138, Italy.
  • Nuclear Medicine Unit, Department of Medicine DIMED, University-Hospital of Padova, Padova, Italy.
  • Nuclear Medicine, Alma Mater Studiorum, University of Bologna, Via Massarenti 9, Bologna, 40138, Italy.
  • Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

ORCID-Profile: Andrea Di Giorgio, Martina Di Franco

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Di Giorgio, A., Siepe, G., Serani, F., Di Franco, M., Malizia, C., Castellucci, P., Fanti, S., & Farolfi, A. (2025). Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07255-6

Vancouver

Di Giorgio A, Siepe G, Serani F, Di Franco M, Malizia C, Castellucci P, et al. Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07255-6

BibTeX
@article{DiGiorgio2025,
  author = {Di Giorgio, Andrea and Siepe, Giambattista and Serani, Francesca and Di Franco, Martina and Malizia, Claudio and Castellucci, Paolo and Fanti, Stefano and Farolfi, Andrea},
  title = {Long-term outcomes of PSMA PET/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07255-6}
}
Kostenlos starten →